Sign up for ICER's Weekly View Newsletter

 

Weekly View


June 5, 2026

From the desk of Priya Ranade

Good morning, everyone.

From Dan Ollendorf, PhD, MPH, ICER’s Chief Scientific Officer and Director of HTA Methods and Engagement:



Now that ISPOR 2026 is in the books, it’s a great time to reflect on the experience and key learnings. But first and foremost, I want to share my great pride about the breadth and depth of research presented by the ICER team, which covered a wide range of topics from enhancing economic models with patient input and AI, to better understanding clinical and economic evidence, to balancing innovation and affordability.


It was also particularly gratifying to hear a plenary speaker commend ICER as a health technology assessment (HTA) leader for the US. That’s what 20 years of hard and thoughtful work will do!


The broader conference provided many important themes to digest and consider. Three topics stood out to me:


  • The continued importance of health economics outcomes research (HEOR): Presenters consistently highlighted the advantages of clearly outlining the value propositions for new innovations using HEOR – this is especially important for transformational or potentially curative treatments that can make a real difference for patients.


  •  AI was ever-present: With presentations on AI-enabled literature synthesis, RWE analyses, and economic modeling, there was much discussion on how AI could be utilized in the HEOR space. Unlike prior years, however, there were also important conversations about the appropriate level of governance, risk mitigation, and human interaction needed to make AI a reality.


  • An emphasis on global pricing strategies: And last but certainly not least, there were conversations about the shift of pricing policy from a jurisdiction-specific conversation to a global one, with the impact of US trade policy at the forefront. Implications for product launch strategy, pressure on foreign governments to raise prices, potential shifts in the location and level of investment in biopharmaceutical development – you name it, it was discussed.


Many questions remain, but I left the conference feeling hopeful. ICER’s commitment — along with that of many others — to evidence-based analysis, transparency, and ethics will remain central to HEOR discussions.

Let's see what happened this week...

 
Pharmaceutical News

MUST READS

Medicare still won’t say how much covering obesity drugs will cost

STAT

Medicare is advertising that adults 65 and older can get Wegovy and Zepbound, specifically for weight loss, starting in July for $50 a month. But the agency still is not sharing how much this will cost taxpayers, who will foot most of the bill.


There is a lot at stake for the public and Medicare beneficiaries. The temporary coverage of obesity medications, which sidesteps federal law, will unleash millions of new patients and billions of dollars in revenue for the drugs’ manufacturers, Eli Lilly and Novo Nordisk.

Trump signs off on HHS overhaul of childhood vaccine schedule with new executive order

Fierce Healthcare

President Donald Trump has endorsed a decision by the Department of Health and Human Services to cut down the number of required vaccinations for children, directing federal agencies to align their policies with HHS' assessment.


The new schedule removes recommendations for flu and Covid vaccines for children. Also chopped were shots for rotavirus, meningitis, hepatitis A and hepatitis B. These shots can still be administered, but only after consultation with a healthcare specialist.

How Health Insurance Coverage Denials Affect Americans

The Commonwealth Fund

The Commonwealth Fund 2025 Affordability Survey on patients’ and families’ experiences with insurance coverage denials found:

 

  • One in five (21%) U.S. working-age adults with private insurance reported that they or a family member had experienced an insurance company denial of coverage for medical care recommended by a doctor in the past year, either before or after the care was provided.

 

  • Forty-one percent of people who experienced a prior authorization denial said it led to a delay in medical care, and more than a quarter (28%) said a health problem got worse because of it.

 

  • Among people who experienced a claim denial, nearly 70 percent said it cost them or their household more money. More than two in five (43%) adults who experienced a claim denial reported that the denial led to medical debt that they are still paying off.

 

ICER’s work on fair access for prescription drugs has established ethical criteria that payers should follow when designing coverage policies, which includes recommendations on prior authorization protocols.

Oz: All MFN Deals To End When Admin Ends, Trump Rx To Host 160 More Drugs

Inside Health Policy

CMS Administrator Mehmet Oz on Tuesday (June 2) confirmed that the most favored nation agreements the Trump administration struck with 17 drug companies to make certain drugs available at a reduced price on TrumpRx will end when the administration is over. He urged Congress to codify the deals to keep them ongoing regardless of a shift in power.

FDA details flexibilities for new cell and gene therapies to leverage past data

Endpoints News

The FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER draft guidance released Tuesday. Building off more than four dozen cell and gene therapy approvals, the 23-page draft offers more granular guidance on what types of information can be pulled from internal platforms and publicly available sources.


The guidance is part of a wider push from the FDA’s Office of Therapeutic Products (OTP) to ease the regulatory hurdles for these advanced therapies, particularly as manufacturing questions have held up some approvals. 

OTHER HEADLINES

 

Join ICER!

 

Want to work for a fast-paced, mission-driven organization? Look no further! ICER is looking to expand our team:



 

Key Upcoming Dates

 
  • 6/8: Narcolepsy -- Final Evidence Report
  • 6/11: Covid-19 -- Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email